The company is committed to identifying and investing in promising technologies related to cancer treatment, including tools, technologies, and components of contemporary drug development. Aglaia's specialized knowledge in translating biomedical discoveries into novel products is a key asset, and the company selects, develops, and commercializes breakthrough inventions with the potential to transform cancer treatment. Opportunities may come from research centers or corporate spinouts, and Aglaia's track record demonstrates its ability to mature early-stage inventions into successful anti-cancer drugs. For more information, visit www.aglaia-oncology.com.